Strong CAGR to Propel in the Non-Alcoholic Steatohepatitis (NASH) Market and Beyond upto $19.07 Billion by 2029
Discover trends, market shifts, and competitive outlooks for the non-alcoholic steatohepatitis (nash) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#How Fast Is The Non-Alcoholic Steatohepatitis (NASH) Market Expected to Grow Between 2025 And 2029?#_x000D_
Recently, there has been an exponential surge in the size of the non-alcoholic steatohepatitis (NASH) market. It is predicted to expand from $4.5 billion in 2024 to $6.13 billion in 2025, with a compound annual growth rate (CAGR) of 36.1%. The historical growth pattern can be linked to an increase in NASH prevalence, the obesity crisis, heightened awareness and diagnosis, changes in lifestyle and eating habits, along with the development of the healthcare infrastructure._x000D_
_x000D_
Expectations are high for the non-alcoholic steatohepatitis (NASH) market to experience a surge in size over the coming years. By 2029, the market is projected to reach $19.07 billion, with a compound annual growth rate (CAGR) of 32.8%. This anticipated growth during the forecast period can be linked to various factors such as advancements in NASH medication, a rise in screening initiatives for NASH, increased spending in the health sector, joint research initiatives, as well as support and regulatory measures from the government. Several trends expected to prevail in this period comprise a greater focus on lifestyle modifications and educating patients, amplified partnerships in clinical research, advancements in regulatory and pathway designations, and incorporating artificial intelligence in diagnosis and monitoring._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp_x000D_
_x000D_
#Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?#_x000D_
The increase in obesity cases is catapulting the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat, raising health risks and manifesting as body weight exceeding the advisable limit for a person’s height. Non-alcoholic fatty liver disease prevalence has surged, owing to the escalating obesity epidemic, making NASH potentially the most common cause of serious liver disease in the upcoming years. Consequently, this sparks a demand for NASH treatments and related drugs. In confirmation, the World Health Organization (WHO), a UK-based global public health institution, noted in March 2024, that around 2.5 billion adults aged 18 and over were identified as overweight in 2022, with 890 million of them being obese. Therefore, the escalating number of obesity cases is set to spur the growth of the non-alcoholic steatohepatitis (NASH) market._x000D_
_x000D_
#Which Primary Segments of the Non-Alcoholic Steatohepatitis (NASH) Market Are Driving Growth and Industry Transformations?#_x000D_
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Solid, Liquid_x000D_
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products_x000D_
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity_x000D_
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider_x000D_
5) By Application: Oral, Parenteral_x000D_
_x000D_
Subsegments:_x000D_
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms_x000D_
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp_x000D_
_x000D_
#Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?# Market?#_x000D_
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Which Technological Trends Are Reshaping the Non-Alcoholic Steatohepatitis (NASH) Industry Dynamics?#_x000D_
Prominent businesses in the non-alcoholic steatohepatitis (NASH) sector are concentrating their efforts on the production of thyroid hormone receptor-beta (THR-beta) agonists. These compounds are designed to boost liver metabolism, mitigate liver fat buildup, and optimize liver function. The THR-beta agonists are specific compounds that kindle the thyroid hormone receptor-beta subtype, which plays a crucial role in managing metabolism, growth, and development. For instance, Rezdiffra (resmetirom) was given green light by the US’s Food and Drug Administration in March 2024. It’s a THR-beta agonist and is the inaugural treatment for adults afflicted with noncirrhotic NASH presenting moderate to advanced liver scarring (fibrosis). Rezdiffra operates by selectively stimulating the THR-beta receptor, which mediates lipid metabolism, resulting in a decrease in intrahepatic triglycerides and overall liver fat accumulation._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#What Parameters Are Used to Define the Non-Alcoholic Steatohepatitis (NASH) Market?#_x000D_
Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
